Interferon-β and -γ, but not tumor necrosis factor-α, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus

Cancer

Volumn 79, Issue 5, 1997, Pages 924-934

  Bornstein, Jacob ^a,b   Lahat, Nitza ^a,b   Kinarty, Amalia ^a   Revel, Michel ^c   Abramovici, Haim ^a,b   Shapiro, Sarah ^a  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

human leukocyte antigens; human papillomavirus 16; intercellular adhesion molecule 1; interferon and ; tumor necrosis factor

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; ETIOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; VIRUS CARCINOGENESIS; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; CARCINOMA; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, MHC CLASS I; GENES, MHC CLASS II; HLA ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-BETA; INTERFERON-GAMMA, RECOMBINANT; MEMBRANE PROTEINS; PAPILLOMAVIRIDAE; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 0031040526     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970301)79:5<924::AID-CNCR9>3.0.CO;2-B     Document Type: Article

References (53)

1. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
2. Howley PM. Role of the human papillomavirus in human cancer. Cancer Res 1991;51:50192s-222s.
3. Fuchs PG, Girardi F, Pfister H. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of cervix uteri. Int J Cancer 1988;43:41-5.
4. Benton C, Shahidulla H, Hunter J. Human papillomavirus in the immunosuppressed. Papillomavirus Report 1992; 3:23-6.
5. Porreco R, Penn I, Droeggemuller W, Greer B, Makowski M. Gynaecologic malignancies in immunosuppressed organ homograft recipients. Obstet Gynecol 1975;45:359-64.
6. Viac J, Soler C, Chardonnet Y, Euvrard S, Schmitt D. Expression of immune associated surface antigens of keratinocytes in human papillomavirus-derived lesions. Immunobiology 1993;188:392-402.
7. Tay SK, Jenkins D, Maddox P, Singer A. Lymphocyte pheno-types in cervical intraepithelial neoplasia and human papillomavirus infection. Br J Obstet Gynaecol 1987;94:16-21.
8. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-9.
9. Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990;20:1893-987.
10. Connor ME, Stern PL. Loss of MHC class I expression in cervical carcinomas. Int J Cancer 1990;46:1029-34.
11. Cromme FV, Meijer CJLM, Snijders PJF, Uytelinde A, Kenemans P, Helmerhorst Th, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in pre-malignant and malignant cervical lesions. Br J Cancer 1993;67:1372-80.
12. Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA-class-II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992;52:4009-16.
13. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
14. Coleman N, Greenfield IM, Hare J, Kruger-Gray H, Chain BM, Stanley MA. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratino-cytes. Am J Pathol 1993;143:355-67.
15. Piccini LA, Mackenzie WA, Platzer M, Davies TF. Lymphokine regulation of HLA-DR gene expression in human thyroid cell monolayers. J Clin Endocrinol Metab 1990;64:543-54.
16. Lahat N, Hirose W, Davies TF. Enhanced induction of thyroid cell MHC class II antigen expression in rats highly responsive to thyroglobulin. Endocrinology 1989;24:1754-9.
17. Nickoloff B, Griffiths CE, Barker JN. The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease-1990 update. J Invest Dermatol 1990;94:151s-8s.
18. Dhib-Jalbut SS, Cowan EP. Direct evidence that interferon-β mediates enhanced HLA-class I expression in measles virus-infected cells. J Immunol 1993;151:6248-58.
19. Noronha A, Toscas A, Jensen MA. Interferon-β modulates immune function: implication in multiple sclerosis. Ann Neurol 1990;27:207-10.
20. Horikoshi T, Ezoe K, Nakagawa H, Eguchi H, Hanada N, Hamaoka S. Up-regulation of ICAM-1 expression on human dermal fibroblasts by IFN-β in the presence of TNF-α. FEBS Lett 1995;363:141-4.
21. Bornstein J, Ben-David Y, Atad J, Pascal B, Revel M, Abramovici H. Treatment of cervical intraepithelial neoplasia and invasive squamous cell carcinoma by interferon. Obstet Gynecol Surv 1993;48:251-60.
22. Penna C, Fallani MG, Gordigiani R, Sonni L, Taddei GL, Marchionni M. Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection. Tumori 1994;80:146-50.
23. Iwasaka T, Hayashi Y, Yokoyama M, Hachisuga T, Sugimori H. Interferon γ treatment for cervical intraepithelial neoplasia. Gynecol Oncol 1990;37:96-102.
24. Friedl F, Kimura ITO, Ito Y. Studies on a new cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 1970;135:543-5.
25. Patillo RA, Hussa RO, Story MT, Ruckert ACF, Shalaby MR, Mattingly RF. Tumor antigen and human chorionic gonadotrophin in CaSki cells: a new epidermoid-cancer cell line. Science 1977;196:1456-8.
26. Hosaka S, Akahoshi T, Wada C. Expression of the chemokine superfamily in rheumatoid artheritis. Clin Exp Immunol 1994;97:451-7.
27. Pang G, Couch L, Batey R, Vlancy R, Cripps A. GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with LPS, IL-1α, and TNF-α. Clin Exp Immunol 1994;96:437-43.
28. Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994; 56:314-9.
29. Gosh AK, Moore M. Tumour-infiltrating lymphocytes in cervical carcinoma. Eur J Cancer 1992;11:1910-6.
30. Malejczyk J, Malejczyk M, Kock A, Urbanski A, Majewski S, Hunzelman N, et al. Autocrine growth limitation of human papillomavirus type 16 harboring keratinocytes by constitutively released tumor necrosis factor-α. J Immunol 1992;149:2702-8.
31. Arany I, Rady P, Tyring SK. Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGFβ1/IFNβ cytokine pathway. Antiviral Res 1994;23:131-41.
32. Miller A, Lanir N, Shapiro S, Revel M, Honigman S, Kinarty A, et al. Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases. Neuroimmunology 1996;64:151-61.
33. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA. Antagonism of interferon-beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Multiple Sclerosis 1996;1:S5-11.
34. Lahat N, Sheinfeld M, Sobel E, Kinarty A, Kraiem Z. Divergent effects of cytokines on human leukocyte antigen-DR antigen expression of neoplastic and nonneoplastic thyroid cells. Cancer 1992;69:1801-7.
35. Malejczyk J, Malejczyk M, Majewski S, Breitburd F, Luger TA, Jablonska S, et al. Increased tumorigenicity of human keratinocytes harbouring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-α-mediated growth limitation. Int J Cancer 1994;56:593-8.
36. Maudsley DJ, Pound JD. Modulation of MHC antigen expression by viruses and oncogenes. Immunol Today 1991; 12:429-31.
37. Lahat N, Sheinfeld M, Baron E, Sobel E, Kraiem Z. Divergent effects of thyroid HLA antigens on T and natural killer (NK) cytotoxicity. Autoimmunity 1992;13:201-7.
38. Proffitt JL, Sharma E, Blair GE. Adenovirus 12-mediated down-regulation of the major histocompatibility complex (MHC) class I promoter: identification of a negative regulatory element responsive to Ad12 EIA. Nucleic Acids Res 1994;22:4779-88.
39. Huibregtse JM, Scheffner M. Mechanisms of tumor suppressor protein inactivation by the human papillomavirus E6 and E7 oncoproteins. Semin Virol 1994;5:357-67.
40. Hilders CGJM, Houbiers JGA, Krul EJT, Fleuren GJ. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994;101:5-12.
41. Williams DB, Barber BH, Flavell RA, Allen H. Role of β2-microglobulin in the intracellular transport and surface expression of murine class-I histocompatibility molecules. J Immunol 1989;142:2796-801.
42. Versteeg RK, Kruse-Wolters M, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, et al. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 1989;170:621-35.
43. Cromme FV, Snijders LM, van den Brule AJC, Kenemans P, Meijer CJLM, Walhoomers JMM. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 1993;8:2969-75.
44. Yasuma Y, Tasaki K, McCarron RM, Frerichs KU, Spatz M, Hallenbeck JM. Inflammation and ischemia: implication for treatment. In: Krieglstein J, Oberpichler-Schwenk H, editors. Pharmacology of cerebralischemia. Stuttgart: Medpharm Scientific Publishers Stuttgart, 1994:437-43.
45. Natali PG, Nictra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990;50:1271-8.
46. Viac J, Guerin-Reverchon I, Chardonnet Y, Bremond A. Langerhans cells and epithelial cell modifications in cervical intraepithelial neoplasia: correlation with human papillomavirus infection. Immunobiology 1990;180:328-38.
47. Hughes RG, Norval M, Howie SEM. Expression of major histocompatibility class II antigen by langerhans' cells in cervical intraepithelial neoplasia. J Clin Pathol 1988;41: 253-9.
48. Hawthorn RJS, Murdoch JB, MacLean AB, MacKie RM. Langerhans' cells and subtypes of human papillomavirus in cervical intraepithelial neoplasia. BMJ 1988;297:643-6.
49. Tay SK, Jenkins D, Maddox P, Hogg N, Singer A. Tissue macrophage response in human papillomavirus infection and cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1987;94:1094-7.
50. Castello G, Esposito G, Stellato G, Dalla-Mora L, Abate G, Germano A. Immunological abnormalities in patients with cervical carcinoma. Gynecol Oncol 1986;25:61-4.
51. + T lymphocytes are recruited to neoplastic cervix. J Clin Immunol 1995;15:130-6.
52. Garzetti GG, Ciavattini A, Romanini C, Goteri G, Tranquilli AL, Muzzioli M, et al. Interferon alpha 2b treatment of cervical intraepithelial neoplasia grade 2: modulation of natural killer cell. Gynecol Obstet Invest 1994;37:204-9.
53. Banks L, Moreau F, Vousden K, Pim D, Matlashewski G. Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. J Immunol 1991; 146:2037-42.